– Jazz to pay an upfront payment of $200 million to PharmaMar
– Opportunity for Jazz to expand its oncology portfolio with lurbinectedin, a late stage asset in relapsed small cell lung cancer (SCLC)
– PharmaMar is also eligible to receive up to $800 million in potential milestone payments in addition to royalties on net…
Get insights on Anike (Penpulimab-kcqx) NPC’s role in first-line treatment and its benefits for patients with nasopharyngeal carcinoma.
Uncover the groundbreaking insights from the CodeBreaK 300 study on treating chemorefractory KRAS G12C-mutated mCRC.
Get informed about Nivolumab MSI-H Colorectal and its FDA approval. Detailed insights from the CHECKMATE-8HW trial await.
Prepare for Oncology Conferences 2025 to 2027. Join leading meetings such as ASCO and SABCS for the latest in cancer research.
Empowering Oncology Professionals with Knowledge, Insights, and Innovation. Medicus Networks, Inc. 45121 Morgan Heights Rd, Temecula, CA 92592 All Rights
Rock the Cancer Warrior T-Shirt! Bold, comfy, and perfect for researchers, nurses, oncologists, and patients. Available in 10 colors—proceeds support cancer awareness. Wear your strength!…
Reflecting on Steve Jobs death, we examine his cancer journey and the evolution of treatments. What if he had today’s options?
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers…
Exciting findings from the BREAKWATER study: encorafenib and cetuximab combination therapy improves treatment outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer.
The Nivolumab CheckMate-274 trial reveals promising data on overall survival in muscle-invasive bladder cancer.
